Your session is about to expire
← Back to Search
Senolytic Agent
Senolytic Drugs Attenuate Osteoarthritis-Related Articular Cartilage Degeneration: A Clinical Trial
Phase 1 & 2
Waitlist Available
Led By Thomas A Evans, MD
Research Sponsored by Steadman Philippon Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months, 12 months, and 18 months (post 1st drug dose)
Summary
This trial tests if Fisetin, a dietary supplement, can help patients with mild to moderate knee osteoarthritis by reducing old cells that cause inflammation and cartilage breakdown.
Eligible Conditions
- Osteoarthritis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months, 12 months, and 18 months (post 1st drug dose)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months, 12 months, and 18 months (post 1st drug dose)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants Experiencing One or More Treatment-Emergent Adverse Event
Secondary study objectives
Change in Levels of Cartilage Degenerating Markers Associated With OA
Change in Levels of Pro-inflammatory Markers Associated With Senescence
Change in Muscle Strength (Isokinetic Dynamometry)
+9 moreSide effects data
From 2023 Phase 1 & 2 trial • 75 Patients • NCT0421098638%
Arthralgia
15%
Pain in Extremity
12%
Lab Findings
12%
Nausea
9%
Fatigue
9%
Back Pain
9%
Headache
6%
Muscle Cramp
6%
Flatulence
6%
Dry Mouth
6%
Rash Maculo-Papular
3%
Covid 19
3%
Neoplasms
3%
Rotator Cuff Injury
3%
Bladder Perforation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Fisetin
Placebo
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: FisetinExperimental Treatment1 Intervention
Fisetin 100 mg capsules (\~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. A second course will be given for two consecutive days (days 31 and 32)
Group II: PlaceboPlacebo Group1 Intervention
Placebo capsules will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. A second course will be given for two consecutive days (days 31 and 32)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fisetin
2016
Completed Phase 2
~250
Find a Location
Who is running the clinical trial?
Office of Naval Research (ONR)FED
14 Previous Clinical Trials
580 Total Patients Enrolled
Steadman Philippon Research InstituteLead Sponsor
10 Previous Clinical Trials
627 Total Patients Enrolled
1 Trials studying Osteoarthritis
100 Patients Enrolled for Osteoarthritis
United States Department of DefenseFED
913 Previous Clinical Trials
334,231 Total Patients Enrolled
2 Trials studying Osteoarthritis
80 Patients Enrolled for Osteoarthritis
Thomas A Evans, MDPrincipal InvestigatorThe Steadman Clinic